214 related articles for article (PubMed ID: 11734597)
1. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel.
Taghian AG; Assaad SI; Niemierko A; Kuter I; Younger J; Schoenthaler R; Roche M; Powell SN
J Natl Cancer Inst; 2001 Dec; 93(23):1806-11. PubMed ID: 11734597
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
Burstein HJ; Bellon JR; Galper S; Lu HM; Kuter I; Taghian AG; Wong J; Gelman R; Bunnell CA; Parker LM; Garber JE; Winer EP; Harris JR; Powell SN
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):496-504. PubMed ID: 16243442
[TBL] [Abstract][Full Text] [Related]
3. Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer?
Taghian AG; Assaad SI; Niemierko A; Floyd SR; Powell SN
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):386-91. PubMed ID: 15890579
[TBL] [Abstract][Full Text] [Related]
4. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
Yu TK; Whitman GJ; Thames HD; Buzdar AU; Strom EA; Perkins GH; Schechter NR; McNeese MD; Kau SW; Thomas ES; Hortobagyi GN; Buchholz TA
J Natl Cancer Inst; 2004 Nov; 96(22):1676-81. PubMed ID: 15547180
[TBL] [Abstract][Full Text] [Related]
5. Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasibility of concurrent treatment.
Ellerbroek N; Martino S; Mautner B; Tao ML; Rose C; Botnick L
Breast J; 2003; 9(2):74-8. PubMed ID: 12603378
[TBL] [Abstract][Full Text] [Related]
6. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
7. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
8. Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy.
Hanna YM; Baglan KL; Stromberg JS; Vicini FA; A Decker D
Breast J; 2002; 8(3):149-53. PubMed ID: 12047471
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
[TBL] [Abstract][Full Text] [Related]
10. Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue.
Lind PA; Marks LB; Jamieson TA; Carter DL; Vredenburgh JJ; Folz RJ; Prosnitz LR
Cancer; 2002 Jun; 94(11):2821-9. PubMed ID: 12115368
[TBL] [Abstract][Full Text] [Related]
11. Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk?
Beal K; Hudis C; Norton L; Wagman R; McCormick B
Breast J; 2005; 11(5):317-20. PubMed ID: 16174151
[TBL] [Abstract][Full Text] [Related]
12. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.
Loesch D; Greco FA; Senzer NN; Burris HA; Hainsworth JD; Jones S; Vukelja SJ; Sandbach J; Holmes F; Sedlacek S; Pippen J; Lindquist D; McIntyre K; Blum JL; Modiano MR; Boehm KA; Zhan F; Asmar L; Robert N
J Clin Oncol; 2010 Jun; 28(18):2958-65. PubMed ID: 20479419
[TBL] [Abstract][Full Text] [Related]
13. Current status of paclitaxel in the treatment of breast cancer.
O'Shaughnessy JA; Cowan KH
Breast Cancer Res Treat; 1995; 33(1):27-37. PubMed ID: 7749130
[TBL] [Abstract][Full Text] [Related]
14. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
Henderson IC; Berry DA; Demetri GD; Cirrincione CT; Goldstein LJ; Martino S; Ingle JN; Cooper MR; Hayes DF; Tkaczuk KH; Fleming G; Holland JF; Duggan DB; Carpenter JT; Frei E; Schilsky RL; Wood WC; Muss HB; Norton L
J Clin Oncol; 2003 Mar; 21(6):976-83. PubMed ID: 12637460
[TBL] [Abstract][Full Text] [Related]
15. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy.
Lingos TI; Recht A; Vicini F; Abner A; Silver B; Harris JR
Int J Radiat Oncol Biol Phys; 1991 Jul; 21(2):355-60. PubMed ID: 2061112
[TBL] [Abstract][Full Text] [Related]
16. Radiation pneumonitis following twice-daily radiotherapy with concurrent carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer.
Kobayashi H; Uno T; Isobe K; Ueno N; Watanabe M; Harada R; Takiguchi Y; Tatsumi K; Ito H
Jpn J Clin Oncol; 2010 May; 40(5):464-9. PubMed ID: 20085905
[TBL] [Abstract][Full Text] [Related]
17. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial.
Formenti SC; Volm M; Skinner KA; Spicer D; Cohen D; Perez E; Bettini AC; Groshen S; Gee C; Florentine B; Press M; Danenberg P; Muggia F
J Clin Oncol; 2003 Mar; 21(5):864-70. PubMed ID: 12610186
[TBL] [Abstract][Full Text] [Related]
18. Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast cancer.
Abner AL; Recht A; Vicini FA; Silver B; Hayes D; Come S; Harris JR
Int J Radiat Oncol Biol Phys; 1991 Jul; 21(2):331-8. PubMed ID: 2061109
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.
Halyard MY; Pisansky TM; Dueck AC; Suman V; Pierce L; Solin L; Marks L; Davidson N; Martino S; Kaufman P; Kutteh L; Dakhil SR; Perez EA
J Clin Oncol; 2009 Jun; 27(16):2638-44. PubMed ID: 19349549
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
De Giorgi U; Giannini M; Frassineti L; Kopf B; Palazzi S; Giovannini N; Zumaglini F; Rosti G; Emiliani E; Marangolo M
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1165-9. PubMed ID: 16682141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
